The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OCPNY | -30.42% | -34.04% | -7.98% | +502% |
| S&P | +16.23% | +94.45% | +14.22% | +1,050% |
Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.43B | -5.2% |
| Gross Profit | $935.21M | -6.7% |
| Gross Margin | 65.43% | -1.1% |
| Market Cap | $13.29B | -27.2% |
| Market Cap / Employee | $0.45M | 0.0% |
| Employees | 29.3K | 1.6% |
| Net Income | $62.23M | -34.4% |
| EBITDA | $201.78M | -42.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.67B | -2.1% |
| Accounts Receivable | $1.27B | 10.7% |
| Inventory | 1.4K | 19.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.60B | 39.8% |
| Short Term Debt | $311.52M | -28.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 7.66% | 6.0% |
| Return On Invested Capital | 10.41% | 0.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$195.71M | -305.8% |
| Operating Free Cash Flow | -$105.22M | -170.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 44.25 | 31.33 | 19.18 | 18.15 | -89.44% |
| Price to Book | 4.51 | 3.46 | 3.14 | 2.64 | -29.85% |
| Price to Sales | 3.39 | 2.62 | 2.26 | 2.08 | -28.81% |
| Price to Tangible Book Value | 7.07 | 5.50 | 5.09 | 4.16 | -29.28% |
| Price to Free Cash Flow TTM | 40.39 | 21.70 | 18.32 | 27.08 | -41.04% |
| Enterprise Value to EBITDA | 50.97 | 44.13 | 29.68 | 67.56 | 26.60% |
| Free Cash Flow Yield | 2.5% | 4.6% | 5.5% | 3.7% | 69.60% |
| Return on Equity | 11.2% | 12.7% | 15.5% | 14.9% | 363.41% |
| Total Debt | $1.72B | $1.48B | $1.95B | $1.92B | 21.07% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
